<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00175227</url>
  </required_header>
  <id_info>
    <org_study_id>HSRIF #96-20</org_study_id>
    <nct_id>NCT00175227</nct_id>
  </id_info>
  <brief_title>Prevention of Contrast-Induced Nephropathy</brief_title>
  <official_title>Prevention of Contrast-Induced Nephropathy: a Randomized Controlled Trial of Saline + Furosemide + Mannitol in High Risk Patients Undergoing Cardiac Angiography</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alberta</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Alberta Heritage Foundation for Medical Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Alberta</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with pre-existing kidney disease are at high risk of acute renal failure when
      exposed to radio-contrast dyes, for example during a cardiac angiogram.

      The investigators hypothesize that an infusion of saline + furosemide + mannitol will reduce
      rates of contrast-induced nephropathy when compared with saline infusion controls.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with pre-existing kidney disease are at high risk of acute renal failure when
      exposed to radio-contrast dyes, for example during a cardiac angiogram.

      We hypothesize that an infusion of saline + furosemide + mannitol will reduce rates of
      contrast-induced nephropathy when compared with saline infusion controls.

      We define an episode of contrast nephropathy using the conventional often published
      definition of a 25% relative increase in serum creatinine OR a 44 umol absolute increase in
      serum creatinine within 48 hours of contrast exposure.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 1996</start_date>
  <primary_completion_date type="Actual">October 2000</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients that develop contrast-induced nephropathy after cardiac angiography</measure>
    <time_frame>Within 48 hours of angiogram</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety of the intervention based on transfer to ICU, need for dialysis, or death</measure>
    <time_frame>During hospitalization episode</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse clinical events and measures of renal function</measure>
    <time_frame>6 weeks post-angiogram</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health related quality of life</measure>
    <time_frame>6 weeks post-angiogram</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subgroup analyses based on (a) diabetes; (b) amount of contrast; and (c) baseline creatinine</measure>
    <time_frame>Within 48 hours of angiogram</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Contrast-induced Nephropathy</condition>
  <condition>Acute Renal Failure</condition>
  <condition>Chronic Renal Failure</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Saline hydration + mannitol + furosemide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controls</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline hydration without mannitol or furosemide</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>intravenous saline hydration + mannitol + furosemide</intervention_name>
    <description>500 mls half-normal saline + 25g mannitol + 100 mg furosemide</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>intravenous saline hydration</intervention_name>
    <description>500 mls half-normal saline</description>
    <arm_group_label>Controls</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age &gt; 21 years

          -  serum creatinine &gt; 150 umol/L

          -  able and willing to provide informed consent

        Exclusion Criteria:

          -  known hypersensitivity to contrast, furosemide, or mannitol

          -  unable to tolerate a fluid load (e.g., acute pulmonary edema)

          -  ESRD, on dialysis

          -  previous enrollment in this study or previous contrast administration with the last 2
             weeks

          -  refusal by treating physician
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sumit R Majumdar, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alberta</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alberta Hospitals</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2B7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <results_reference>
    <citation>Majumdar SR, Kjellstrand CM, Tymchak WJ, Hervas-Malo M, Taylor DA, Teo KK. Forced euvolemic diuresis with mannitol and furosemide for prevention of contrast-induced nephropathy in patients with CKD undergoing coronary angiography: a randomized controlled trial. Am J Kidney Dis. 2009 Oct;54(4):602-9. doi: 10.1053/j.ajkd.2009.03.024. Epub 2009 Jun 17.</citation>
    <PMID>19535188</PMID>
  </results_reference>
  <verification_date>May 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 10, 2005</study_first_submitted>
  <study_first_submitted_qc>September 10, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2005</study_first_posted>
  <last_update_submitted>May 9, 2011</last_update_submitted>
  <last_update_submitted_qc>May 9, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 10, 2011</last_update_posted>
  <responsible_party>
    <name_title>Sumit Majumdar/Principal Investigator</name_title>
    <organization>University of Alberta</organization>
  </responsible_party>
  <keyword>contrast-induced nephropathy</keyword>
  <keyword>prevention</keyword>
  <keyword>renal failure</keyword>
  <keyword>cardiac angiogram</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
    <mesh_term>Acute Kidney Injury</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Furosemide</mesh_term>
    <mesh_term>Mannitol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

